See the DrugPatentWatch profile for Haloperidol
How do you convert haloperidol from oral (PO) to intramuscular (IM)?
Clinical conversions are usually based on total daily dose. A common practical rule used in many formularies is:
- PO to IM haloperidol: 1:1 (same total mg/day)
- Example: Haloperidol PO 5 mg/day → ~Haloperidol IM 5 mg/day (split into the same number of doses if you’re using divided dosing).
In real-world settings, clinicians sometimes apply small adjustments depending on urgency, patient response, and local protocol, but the safest “conversion” approach is to follow your institution’s approved conversion table and the prescriber’s order set.
What dose schedule should you use after converting to IM?
After converting the total daily dose, IM dosing is often given in divided doses that match the PO schedule (for example, if PO is given twice daily, IM is frequently given twice daily). If the PO regimen was PRN (as needed), hospitals typically replace that with an ordered scheduled dose or a defined PRN IM dose with clear maximum daily limits.
Is IM haloperidol more potent or less potent than oral?
IM and PO haloperidol deliver the same drug, but onset and absorption differ, so clinicians focus less on “potency” and more on:
- how quickly symptoms need control,
- whether the patient is able to take PO,
- the patient’s prior response,
- and monitoring for adverse effects (especially extrapyramidal symptoms, QT prolongation risk, and sedation).
What dosing details matter most (strength, frequency, and formulation)?
When converting, confirm:
- the mg strength of the oral tablets/liquid,
- the exact daily total (not just the single dose),
- the frequency (e.g., 2x/day vs 3x/day),
- whether the oral dosing was scheduled or PRN,
- and your local IM product concentration (so the volume you draw up is correct).
What could go wrong if the conversion is incorrect?
Underdosing can lead to poor symptom control; overdosing increases risk of:
- severe extrapyramidal symptoms (rigidity, dystonia),
- akathisia,
- excessive sedation/respiratory depression (more likely if combined with other sedating meds),
- and QT prolongation, particularly in patients with cardiac risk factors or electrolyte abnormalities.
Where to find an official conversion table?
For patient-specific and institution-specific conversion guidance, use your facility’s formulary policy or order set. If you want, tell me:
1) the patient’s current PO haloperidol dose (mg and frequency),
2) whether it was scheduled vs PRN, and
3) whether the goal is once now or daily dosing,
and I can help you compute the equivalent total daily IM dose using the common 1:1 mg/day approach and show how it maps to the same number of doses.
Quick calculation example (common 1:1 mg/day)
- If PO is 2 mg three times daily (total 6 mg/day), then IM is commonly set to ~6 mg/day, divided as 2 mg IM TID (or split per the same schedule as PO).
---
If you share the exact PO regimen (e.g., “haloperidol 5 mg PO BID” or “10 mg PO/day PRN”), I’ll convert it to an IM schedule with the right daily total.